BioCryst Pharmaceuticals (NASDAQ:BCRX) Announces Quarterly Earnings Results

BioCryst Pharmaceuticals (NASDAQ:BCRX) posted its quarterly earnings data on Monday. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07), Briefing.com reports. The firm had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. The firm’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.19) earnings per share.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock remained flat at $7.73 during mid-day trading on Thursday. The company’s stock had a trading volume of 560,573 shares, compared to its average volume of 2,970,595. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.88. The firm’s 50-day moving average is $7.80 and its two-hundred day moving average is $6.98. The stock has a market cap of $1.60 billion, a P/E ratio of -12.67 and a beta of 1.89.

Analyst Upgrades and Downgrades

Several research analysts have commented on BCRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday. Barclays boosted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research note on Tuesday. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Finally, JMP Securities boosted their target price on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $14.67.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.